exRNAdisease

Entry Detail

---



General Information

Database ID: exR0357756 RNA Name: hsa-miR-520c-3p RNA Type: miRNA Chromosome: chr19 Starnd: + Coordinate: Start Site(bp): 53707506 End Site(bp): 53707527 External Links: hsa-miR-520c-3p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE98181 Description: Circulating miRNA profiles from serum of women at high-risk for breast cancer Experimental Design: Cancer vs Control Case Disease Type: Breast Cancer Case Disease SubType: NA Case Sample: Breast Cancer Control Sample: Healthy Number of Case: 24 Number of Control: 24 Number of Samples: 48

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand PDRG1 chr20 31944337 31952046 - NAA16 chr13 41311267 41377030 + IFNAR1 chr21 33324429 33359864 + FYCO1 chr3 45917899 45995824 - MSL1 chr17 40121971 40136917 + ZFAND4 chr10 45615500 45672780 - CLCN6 chr1 11806096 11848079 + SYAP1 chrX 16719612 16765340 + AMPD2 chr1 109616104 109632053 + EIF5A2 chr3 170888418 170908644 - PTP4A1 chr6 63521746 63583436 + TNS1 chr2 217799588 218033982 - CAMK2N1 chr1 20482391 20486210 - RPP14 chr3 58306247 58324695 + PHC3 chr3 170086732 170181749 - HTD2 chr3 58306262 58318574 + MBP chr18 76978827 77133683 - SLC7A2 chr8 17497088 17570573 + TRIB1 chr8 125430358 125438403 + SIRPA chr20 1894167 1940592 + CCSAP chr1 229321011 229343294 - SRRT chr7 100875103 100888664 + CHD9 chr16 53055033 53329150 + FAM177A1 chr14 35044907 35113130 + PLAGL2 chr20 32192504 32207743 - CLIP4 chr2 29097705 29189643 + NPAS2 chr2 100820139 100996829 + LONP2 chr16 48244300 48363122 + KLHL28 chr14 44924319 45042322 - APP chr21 25880550 26171128 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000943 chr19 47421744 47440665 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AL049840.4 chr14 103694516 103695050 - ARHGAP27P1-BPTFP1-KPNA2P3 chr17 64749663 64781707 - FGD5-AS1 chr3 14920347 14948424 - MIR17HG chr13 91347820 91354579 + NEAT1 chr11 65422774 65445540 + NORAD chr20 36045618 36051018 - SNHG16 chr17 76557764 76565348 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE98181 Sample Source: Blood Source Fraction: Serum Platform: GPL21572 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 2546 Sample treatment protocol: Serum is obtained from coagulated whole blood samples by centrifugation at 3000 rpm for 10 minutes. RNA Extract protocol: RNA was isolated from a 200ul serum aliquot using the miRNeasy Serum Plasma kit with ce-miR-39 spike-in (QIAGEN), QIAcube (QIAGEN) automation, and eluted with 14uL of nuclease-free water. RNA library preparation protocol: Exactly 8ul of RNA was tagged with a Poly-A tail, using an ATP driven reaction from the Affymetrix® FlashTag™ Biotin HSR RNA Labeling Kit.

Reference

PMID: 29348816 Title: Development of a predictive miRNA signature for breast cancer risk among high-risk women. Author: Farina NH, Ramsey JE, Cuke ME, Ahern TP, Shirley DJ, Stein JL, Stein GS, Lian JB, Wood ME Journal: Oncotarget. 2017 Nov 28;8(68):112170-112183. Description: We evaluated the ability of C-miRNAs to identify women most likely to develop breast cancer by profiling miRNA from serum obtained long before diagnosis.